684 patents
Page 8 of 35
Utility
Method for Preparing Amg 416 (Etelcalcetide)
30 Mar 23
A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.
Jeroen BEZEMER, Ying CHEN, Richard CROCKETT, Kevin CROSSLEY, Sheng CUI, Liang HUANG, Sian JONES, Asher LOWER, Krishnakumar RANGANATHAN
Filed: 28 Jun 22
Utility
CXCR7 Inhibitors for the Treatment of Cancer
30 Mar 23
Provided herein are methods of treating cancer in an individual in need thereof, the methods comprising administering to the individual a CXCR7 inhibitor.
Noriko GOTOH, James J. CAMPBELL
Filed: 29 Jul 22
Utility
SMARCA2-VHL Degraders
23 Mar 23
Abhisek BANERJEE, Victor J. CEE, Ning CHEN, Xiaofen LI, Ryan Paul WURZ
Filed: 8 Jan 21
Utility
Systems and Methods for Assessing Cell Growth Rates
23 Mar 23
A method of facilitating a growth assessment for a cell line includes generating an image of a well that contains a medium that was inoculated with at least one cell of the cell line.
Yu Yuan, Tony Y. Wang, Kim H. Le, Christopher Tan, Jasmine Tat, Thorsten Dzidowski
Filed: 4 Mar 21
Utility
Combinations of Antibody Constructs and Inhibitors of Cytokine Release Syndrome and Uses Thereof
23 Mar 23
The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is an antagonist of/an inhibitor of signaling, which is based on an interaction of TNF with its cognate receptor (TNFR), wherein the antagonisation or the inhibition of TNF or its cognate receptor prevents, reduces, or blocks TNF/TNFR mediated signalling.
Benno Rattel, Matthias Friedrich, Oliver Thomas, Tara Arvedson, Jackson Egen, Jason DeVoss, Xiaoting Wang, Grit Lorenczewski
Filed: 22 Jan 21
Utility
Omecamtiv Mecarbil Tablet
23 Mar 23
Provided herein are tablet formulations comprising a core comprising omecamtiv mecarbil, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate of a pharmaceutically acceptable salt thereof; a filler; a binder; a glidant; and a lubricant; and a film coating on the core, the film coating comprising a modified-release polymer and a pore former.
Mingda BI, Yuan-Hon KIANG, Hao LOU
Filed: 10 Feb 21
Utility
RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
16 Mar 23
The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles.
Bin WU, Michael OLLMANN, Oliver HOMANN, Yuan CHENG
Filed: 8 Dec 20
Utility
Pharmaceutical Formulations and Methods of Making the Same
16 Mar 23
The invention relates to the formulation of pharmaceutical compositions of etanercept.
Monica Goss, Nicole Ball
Filed: 16 Sep 22
Utility
Formulations of Human Anti-tslp Antibodies and Methods of Using the Same
16 Mar 23
Provided herein are compositions comprising greater than about 100 mg/mL of an anti-TSLP antibody, a surfactant, proline, and a buffer comprising greater than about 100 mg/mL of an anti-TSLP antibody, a surfactant, proline, and a buffer.
Lauren Roschen, Jennifer Litowski
Filed: 18 Feb 21
Utility
Heterodimeric Bispecific Antibodies
16 Mar 23
Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies.
Wei Yan, Martin J. Pentony, Luis G. Borges, Mark L. Michaels
Filed: 18 Apr 22
Utility
Formulations of Human Anti-tslp Antibodies and Methods of Treating Atopic Dermatitis
16 Mar 23
Provided herein are aqueous compositions comprising (a) an anti-TSLP antibody at a concentration greater than about 140 mg/mL, (b) a surfactant, and (c) at least one basic amino acid or a salt thereof.
Alexis Lueras, Christopher Sloey
Filed: 12 Feb 21
Utility
Adaptation of Platform Hosts to Igf- Media
16 Mar 23
Methods producing a recombinant protein of interest in a mammalian cell culture in media lacking IGF-1 are provided.
Kristine Marie DARIS, Huong Thi Ngoc LE, Eric GISLASON, Trent Phillip MUNRO
Filed: 9 Sep 22
Utility
Treatment of Atopic Dermatitis with Anti-tslp Antibody
9 Mar 23
The present disclosure, relates, in general, to methods of treating atopic dermatitis, including moderate or severe atopic dermatitis, and chronic atopic dermatitis, using an antibody specific for thymic stromal lymphopoietin (TSLP).
Jane R. Parnes, Steven Komjathy
Filed: 12 Feb 21
Utility
Multivariate Bracketing Approach for Sterile Filter Validation
9 Mar 23
A method of reducing resource utilization for sterile filter validation includes obtaining historical datasets that each include respective values of a plurality of parameters associated with a respective sterile filtration process for a respective protein molecule, and generating, by processing the plurality of historical datasets, a PCA model.
Carl G. Kolvenbach, Fuat Doymaz, Wenchang Ji
Filed: 1 Feb 21
Utility
Method of Antigen-Binding Protein Production
2 Mar 23
The present disclosure relates to methods of re-oxidizing an antigen-binding protein.
Elaheh Binabaji, Chio Mui Chan, Hadley Krizner, Junfen Ma, Diana Woehle
Filed: 24 Aug 22
Utility
Electrophoretic Mass Spectrometry Probes and Systems and Uses Thereof
2 Mar 23
The invention generally relates to electrophoretic mass spectrometry probes and systems and methods of uses thereof.
Robert Graham Cooks, Tawnya Flick
Filed: 2 Nov 22
Utility
Antibodies Directed to HER-3 and Uses Thereof
23 Feb 23
The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same.
MIKE ROTHE, MARTIN TREDER, ERIC BORGES, LARRY GREEN, SUSANNE HARTMANN
Filed: 4 Mar 22
Utility
V-C-FC-V-C Antibody
23 Feb 23
Described herein is a dimeric, bispecific antibody format.
Mark L. Michaels, Luis G. Borges, Wei Yan
Filed: 23 Mar 22
Utility
Long Life Polypeptide Binding Molecules
23 Feb 23
The present invention relates to a binding molecule comprising at least three domains comprised in at least one polypeptide chain, wherein the first binding domain is a binding domain which is capable of binding to a cell surface molecule on a target cell, the second binding domain is a binding domain which is capable of binding to the T cell CD3 receptor complex, and the third domain is a binding domain which is capable of binding to serum albumin, wherein said third domain is positioned at the C-terminus of said second domain.
Peter Kufer, Tobias Raum, Ralf Lutterbüse, Markus Muenz, Johannes Brozy, Majk Kvesic, Patrick Hoffmann
Filed: 11 Mar 22
Utility
Methods for Harvesting Biomolecules
23 Feb 23
The disclosure provides methods of purifying native and recombinant biomolecules, e.g., proteins, from mammalian cells using purification protocols incorporating harvest recovery operations involving decanter centrifugation of at least one target biomolecule from at least one particulate component of cell culture fluid.
Thomas Clark Pearson, Sarah Whetstone, Jeremy S. Conner
Filed: 22 Jan 21